ClinicaliQ Trial Snapshot
- Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4). — Recruiting • Phase III • NCT06641414.
- GLORA-4 Trial Summary.
- Adding lisaftoclax to azacitidine improves survival in newly diagnosed high-risk myelodysplastic syndrome compared to azacitidine alone.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
A global multicenter, randomized, double-blind, placebo-controlled, pivotal phase III study. To evaluate overall survival (OS) of lisaftoclax (APG-2575) combined with azacitidine (AZA) vs. placebo combined with azacitidine in newly diagnosed patients with HR-MDS. Conditions: Higher-risk Myelodysplastic Syndrome Interventions: Lisaftoclax (APG-2575), Azacitidine Injection, Placebo Lead Sponsor: Ascentage Pharma Group Inc. Planned Enrollment: 490 participants